Table 1 Completed clinical trials of approved PD-1/PD-L1 inhibitors in combination with other approved treatment strategy

PD-1

Nivolumab

Tivozanib

Anti-angiogenesis therapy

RCC

Phase 1, 2

NCT03136627

Cabozantinib

Anti-angiogenesis therapy

Breast cancer

Phase 2

NCT03316586

Bevacizumab

Anti-angiogenesis therapy

Hepatocellular carcinoma

Phase 2

NCT04393220

Carotuximab

Anti-angiogenesis therapy

NSCLC

Phase 1

NCT03181308

Pomalidomide

Anti-angiogenesis therapy

Nervous system lymphoma

Phase 1

NCT03798314

Ramucirumab

Anti-angiogenesis therapy

Gastric cancer; GEJ Cancer

Phase 1, 2

NCT02999295

Pazopanib + sunitinib + ipilimumab

Anti-angiogenesis therapy + targeted therapy (multiple kinases) + CTLA-4 antibody

RCC

Phase 1

NCT01472081/CheckMate 016

Pemetrexed + paclitaxel + veliparib + carboplatin

Chemotherapy

NSCLC

Phase 1

NCT02944396

Bendamustine hydrochloride

Chemotherapy

Hodgkin's lymphoma

Phase 1, 2

NCT03343652

Idarubicin + cytarabine + solu-medrol + dexamethasone

Chemotherapy

AML

Phase 1, 2

NCT02464657

Carboplatin + pemetrexed + ipilimumab

Chemotherapy + CTLA-4 antibody

NSCLC

Phase 2

NCT03256136

TG4010 + chemotherapy

Chemotherapy + Other treatment

NSCLC

Phase 2

NCT03353675

Cyclophosphamide + fludarabine + TIL infusion + interleukin-2 + ipilimumab

Chemotherapy + other treatment + CTLA-4 antibody

Ovarian Cancer

Phase 1, 2

NCT03287674

PD-1

Nivolumab

Ipilimumab

CTLA-4 antibody

Melanoma

Phase 1

NCT01621490

Ipilimumab

CTLA-4 antibody

Melanoma

Phase 3

NCT02599402

Ipilimumab

CTLA-4 antibody

Melanoma

Phase 2

NCT02320058

Ipilimumab

CTLA-4 antibody

ED-SCLC

Phase 3

NCT02538666

Ipilimumab

CTLA-4 antibody

Melanoma

Phase 3

NCT02714218

Ipilimumab

CTLA-4 antibody

Melanoma

Phase 3

NCT03068455

Ipilimumab

CTLA-4 antibody

Urothelial carcinoma

Phase 1

NCT03387761

Ipilimumab

CTLA-4 antibody

RCC

Phase 2

NCT03029780

Ipilimumab

CTLA-4 antibody

MPM

Phase 2

NCT02716272

Ipilimumab

CTLA-4 antibody

Melanoma

n.a

NCT03438279

Ipilimumab

CTLA-4 antibody

Melanoma

Phase 1, 2

NCT02941744

Ipilimumab

CTLA-4 antibody

Melanoma

Phase 2

NCT02731729

Ipilimumab

CTLA-4 antibody

Malignant pleural mesothelioma

Phase 2

NCT03048474

Ipilimumab

CTLA-4 antibody

Melanoma

Phase 2

NCT01783938/CheckMate 064

Ipilimumab

CTLA-4 antibody

Cancer

NCT03165409

Ipilimumab + SBRT

CTLA-4 antibody + radiotherapy

RCC; kidney cancer

Phase 2

NCT03065179

Ipilimumab + radiotherapy

CTLA-4 antibody + radiotherapy

Melanoma

Phase 1

NCT02659540

Ipilimumab + surgery

CTLA-4 antibody + surgery

Head and neck carcinoma

Phase 1, 2

NCT03003637

Ipilimumab + enzalutamide

CTLA-4 antibody + targeted therapy (AR)

Prostate cancer

Phase 2

NCT02601014

Interferon γ

Other treatment

Solid tumor

Phase 1

NCT02614456

Interleukin-2

Other treatment

RCC

Phase 1, 2

NCT02989714

PD-1

Nivolumab

Tumor biopsy specimens + blood samples

Other treatment

Melanoma

n.a

NCT03348891

JS001 + pembrolizumab

PD-1 antibody

Carcinoma; hepatocellular

Phase 2

NCT03939975

BDCA-1 + myDC + avelumab + ipilimumab

PD-L1 antibodies + CTLA-4 antibody + Other treatment

Solid tumor

Phase 1

NCT03707808

Mogamulizumab

Targeted therapy (CCR4)

Solid tumor

Phase 1

NCT02476123

Mogamulizumab

Targeted therapy (CCR4)

Solid tumor

Phase 1, 2

NCT02705105

Mogamulizumab

Targeted therapy (CCR4)

Solid cancer

Phase 1

NCT02946671

Brentuximab vedotin

Targeted therapy (CD30)

Hodgkin lymphoma

Phase 1, 2

NCT02572167

Brentuximab vedotin

Targeted therapy (CD30)

Hodgkin lymphoma

Phase 3

NCT03138499

Daratumumab

Targeted therapy (CD38)

NSCLC;TNBC

Phase 1, 2

NCT03098550

X4P-001

Targeted therapy (CXCR4)

RCC

Phase 1, 2

NCT02923531

Cetuximab + cisplatin + radiotherapy

Targeted therapy (EGFR) + chemotherapy + radiotherapy

Squamous cell head and neck cancer

Phase 3

NCT03349710

Entinostat

Targeted therapy (HDAC)

Cholangiocarcinoma; pancreatic adenocarcinoma

Phase 2

NCT03250273

Vopratelimab + ipilimumab + pembrolizumab

Targeted therapy (ICOS) + CTLA-4 antibody + PD-1 antibody

Solid tumor

Phase 1, 2

NCT02904226

Binimetinib + ipilimumab

Targeted therapy (MEK1/2) + CTLA-4 antibody

Colorectal cancer

Phase 2

NCT03271047

Regorafenib

Targeted therapy (multiple kinases)

Solid tumor

Phase 1, 2

NCT03406871

PD-1

Nivolumab

Dasatinib

Targeted therapy (multiple kinases)

Myeloid leukemia

Phase 1

NCT02011945

BBI503 + doxorubicin + pembrolizumab + paclitaxel + sunitinib

Targeted therapy (multiple kinases) + Chemotherapy

Cancer

Phase 1

NCT02483247

Omaveloxolone capsules + ipilimumab

Targeted therapy (NF-κB) + CTLA-4 antibody

Melanoma

Phase 1, 2

NCT02259231

INCAGN01949 + ipilimumab

Targeted therapy (OX40) + CTLA-4 antibody

Malignancy

Phase 1, 2

NCT03241173

Elotuzumab + pomalidomide + dexamethasone

Targeted therapy (SLAMF7)

Myeloma

Phase 2

NCT02612779

BBI608 + ipilimumab + pembrolizumab

Targeted therapy (STAT3) + CTLA-4 antibody + PD-1 antibody

Cancer

Phase 1

NCT02467361

DV281 + breath actuated nebulizer

Targeted therapy (TLR) + other treatment

NSCLC

Phase 1

NCT03326752

DS-8273a

Targeted therapy (TRAIL-R2)

Melanoma

Phase 1

NCT02983006

Pembrolizumab

Bevacizumab

Anti-angiogenesis therapy

RCC

Phase 1, 2

NCT02348008

Anlotinib

Anti-angiogenesis therapy

NSCLC

Phase 1, 2

NCT04670107

Pazopanib

Anti-angiogenesis therapy

RCC

Phase 1

NCT02014636/KEYNOTE-018

Lenalidomide

Anti-angiogenesis therapy

Blood Cancer

Phase 1

NCT01953692/KEYNOTE-013

Bevacizumab

Anti-angiogenesis therapy

GBM

Phase 2

NCT02337491

Bevacizumab + cyclophosphamide

Anti-angiogenesis therapy + chemotherapy

Ovarian cancer; fallopian tube cancer; peritoneal cancer

Phase 2

NCT02853318

Doxorubicin

Chemotherapy

Endometrial cancer

Phase 2

NCT03276013

mFOLFOX6

Chemotherapy

Colorectal cancer

Phase 2

NCT02375672

PD-1

Pembrolizumab

Nab-paclitaxel

Chemotherapy

NSCLC

Phase 1, 2

NCT02733250

Azacitidine

Chemotherapy

Colorectal cancer

Phase 2

NCT02260440

Nab-paclitaxel + epirubicin + cyclophosphamide

Chemotherapy

TNBC

Phase 2

NCT03289819

Nab-paclitaxel + doxorubicin + cyclophosphamide + carboplatin + paclitaxel

Chemotherapy

TNBC

Phase 1

NCT02622074/KEYNOTE-173

Oxaliplatin + capecitabine

Chemotherapy

BTC

Phase 2

NCT03111732

Docetaxel

Chemotherapy

NSCLC

Phase 2

NCT02574598

Pemetrexed + carboplatin + cisplatin

Chemotherapy

NSCLC

Phase 2

NCT03664024/KEYNOTE-782

Carboplatin + cisplatin + etoposide

Chemotherapy

SCLC

Phase 3

NCT03066778

Decitabine

Chemotherapy

Myeloid leukemia

Phase 1, 2

NCT02996474

Cisplatin + 5-FU + capecitabine

Chemotherapy

Gastric cancer; gastroesophageal junction adenocarcinoma

Phase 2

NCT02335411/KEYNOTE-059

Chemotherapy

Chemotherapy

Gastric cancer

Phase 2

NCT02918162

Doxorubicin hydrochloride

Chemotherapy

Sarcoma

Phase 1, 2

NCT02888665

Carboplatin

Chemotherapy

Ovarian cancer; fallopian tube cancer; peritoneal cancer

Phase 1, 2

NCT03029598

Cyclophosphamide

Chemotherapy

MBC

Phase 2

NCT03139851

PD-1

Pembrolizumab

Paclitaxel + carboplatin + bevacizumab + pemetrexed + ipilimumab + erlotinib + gefitinib

Chemotherapy + anti-angiogenesis therapy + CTLA-4 antibody + targeted therapy (EGFR)

NSCLC

Phase 1, 2

NCT02039674/KEYNOTE-021

Cisplatin + pemetrexed + carboplatin + paclitaxel + nab-paclitaxel + ipilimumab + etoposide + pegfilgrastim

Chemotherapy + CTLA-4 antibody + other treatment

NSCLC; SCLC

Phase 1

NCT01840579

Niraparib + dostarlimab

Chemotherapy + PD-1 antibody

NSCLC

Phase 2

NCT03308942

Cyclophosphamide + doxorubicin hydrochloride + prednisone + rituximab + vincristine sulfate

Chemotherapy + Targeted therapy (CD20)

Lymphoma

Phase 1

NCT02541565

PegIFN-2b + ipilimumab

CTLA4 antibody + other treatment

RCC; Melanoma

Phase 1, 2

NCT02089685/KEYNOTE-29

Talimogene laherparepvec

Oncolytic virus therapy

Squamous cell carcinoma of the head and neck

Phase 1

NCT02626000/KEYNOTE-137

alfa-2b (HDI)

Other treatment

Melanoma

Phase 1

NCT02339324

Pegzilarginase

Other treatment

SCLC

Phase 1, 2

NCT03371979

PegIFN-2b

Other treatment

Melanoma

Phase 1

NCT02112032

Sintilimab

PD-1 antibody

NSCLC

n.a

NCT05059951

SABR

Radiotherapy

Breast cancer

Phase 1

NCT02303366

Radiation therapy

Radiotherapy

Malignancy

Phase 1

NCT02987166

Radiation therapy

Radiotherapy

RCC

Phase 2

NCT02599779

SBRT

Radiotherapy

Urothelial cancer

Phase 1

NCT02826564

PD-1

Pembrolizumab

Intensity modulated radiation therapy

Radiotherapy

Squamous cell carcinoma of the head and neck

Phase 2

NCT03057613

SABR

Radiotherapy

RCC

Phase 1, 2

NCT02855203

Radiotherapy

Radiotherapy

Cancer

Phase 1

NCT02303990

Hypofractionated stereotactic irradiation (HFSRT) + bevacizumab

Radiotherapy + anti-angiogenesis therapy

Glioma

Phase 1

NCT02313272

Radiation therapy + cisplatin

Radiotherapy + chemotherapy

Squamous cell carcinoma

Phase 1, 2

NCT02759575

Docetaxel + doxorubicin hydrochloride + intensity-modulated radiation therapy + therapeutic conventional surgery

Radiotherapy + chemotherapy + surgery

Thyroid cancer

Phase 2

NCT03211117

Brachytherapy

Radiotherapy + other treatment

Esophageal cancer

Phase 1

NCT02642809

Radiation + Vitamin D + aspirin + lansoprazole + cyclophosphamide + curcumin

Radiotherapy + other treatment + chemotherapy + targeted therapy (p300/CREB)

Cervical cancer; uterine cancer

Phase 2

NCT03192059

Radiotherapy + rituximab + autologous dendritic cells + GM-CSF

Radiotherapy + targeted therapy (CD20) + other treatment

Follicular lymphoma

Phase 2

NCT02677155

SBRT + trametinib

Radiotherapy + targeted therapy(MEK1/2)

Pancreatic cancer

Phase 2

NCT02704156

Dabrafenib + trametinib

Targeted therapy (BRAF) + targeted therapy (MEK)

Melanoma

Phase 1, 2

NCT02130466/KEYNOTE-022

PD-1

Pembrolizumab

Acalabrutinib

Targeted therapy (BTK)

Ovarian cancer

Phase 2

NCT02537444/KEYNOTE191

Acalabrutinib

Targeted therapy (BTK)

Head and neck squamous cell carcinoma

Phase 2

NCT02454179

Acalabrutinib

Targeted therapy (BTK)

NSCLC

Phase 2

NCT02448303

Maraviroc

Targeted therapy (CCR5)

Colorectal cancer

Phase 1

NCT03274804

Abemaciclib + gemcitabine + ramucirumab + samotolisib

Targeted therapy (CDK) + chemotherapy + anti-angiogenesis therapy + targeted therapy (PI3K)

NSCLC

Phase 1

NCT02079636

Necitumumab

Targeted therapy (EGFR)

NSCLC

Phase 1

NCT02451930

Afatinib

Targeted therapy (EGFR)

Squamous cell carcinoma of the lung

Phase 2

NCT03157089

PEGPH20

Targeted therapy (HA)

Solid tumor

Phase 1

NCT02563548

Entinostat

Targeted therapy (HDAC)

Solid tumor

Phase 1

NCT02909452

Vismodegib

Targeted therapy (hedgehog)

Basal cell skin cancer

Phase 1, 2

NCT02690948

Margetuximab

Targeted therapy (HER2)

Gastric cancer; gastroesophageal junction cancer

Phase 1, 2

NCT02689284

Eribulin mesylate

Targeted therapy (microtubule)

TNBC

Phase 1, 2

NCT02513472

Eribulin

Targeted therapy (microtubule)

HR + /HER2- MBC

Phase 2

NCT03222856

Anlotinib

Targeted therapy (multiple kinases)

Ovarian cancer

n.a

NCT05188781

Axitinib

Targeted therapy (multiple kinases)

RCC

Phase 1

NCT02133742

Lenvatinib

Targeted therapy (multiple kinases)

Gastric cancer

Phase 2

NCT03609359

Lenvatinib

Targeted therapy (multiple kinases)

Solid tumor

Phase 1

NCT03006887

PD-1

Pembrolizumab

Saroglitazar

Targeted therapy (multiple kinases)

Biliary cancer

Phase 2

NCT02703714

Niraparib

Targeted therapy (PARP)

TNBC; ovarian cancer

Phase 1, 2

NCT02657889

Ibrutinib

Targeted therapy (brutons tyrosine kinase)

Non-Hodgkin lymphoma

Phase 1

NCT02950220

Ibrutinib + everolimus + docetaxel + paclitaxel + cetuximab

Targeted therapy (brutons tyrosine kinase) + targeted therapy (mTOR) + targeted therapy (EGFR) + chemotherapy

Gastric adenocarcinoma; genitourinary adenocarcinoma

Phase 1, 2

NCT02599324

Afatinib dimaleate

Targeted therapy (EGFR)

NSCLC

Phase 1

NCT02364609

Platinum + afatinib

Targeted therapy (EGFR) + chemotherapy

Squamous Cell Carcinoma of the Lung

NCT04552535

Pemigatinib + gemcitabine + cisplatin + docetaxel + trastuzumab

Targeted therapy (FGFR) + targeted therapy (HER2) + chemotherapy

Malignancies

Phase 1, 2

NCT02393248

ImmunoPulse IL-12

Targeted therapy (IL-12)

Melanoma

Phase 2

NCT02493361

Encorafenib + binimetinib

Targeted therapy (RAF) + targeted therapy (MEK1/2)

Melanoma

Phase 1, 2

NCT02902042

IMP321 (eftilagimod alpha)

Targeted therapy (soluble LAG-3 protein)

Melanoma

Phase 1

NCT02676869

Lenalidomide + dexamethasone

Targeted therapy (TNF-α)

Myeloma

Phase 2

NCT02880228

Paricalcitol

Targeted therapy (vitamin D receptor)

Pancreatic cancer

Phase 2

NCT03331562

Cemiplimab

Ipilimumab

CTLA-4 antibody

Lung cancer

Phase 2

NCT03430063

Ipilimumab + chemotherapy

CTLA-4 antibody + chemotherapy

Lung cancer

Phase 3

NCT03515629

PD-1

Cemiplimab

Hypofractionated radiotherapy + cyclophosphamide + docetaxel + carboplatin + GM-CSF + paclitaxel + pemetrexed

Radiotherapy + chemotherapy

Malignancy

Phase 1

NCT02383212

Isatuximab

Targeted therapy (CD38)

Malignancy

Phase 1, 2

NCT03367819

PD-L1

Atezolizumab

Anlotinib

Anti-angiogenesis therapy

NSCLC

Phase 1, 2

NCT04670107

Bevacizumab + carboplatin + paclitaxel

Anti-angiogenesis therapy + chemotherapy

NSCLC

Phase 3

NCT02366143

Bevacizumab + gemcitabine + leucovorin + Nab-paclitaxe + oxaliplatin + capecitabine + cisplatin

Anti-angiogenesis therapy + chemotherapy

Solid tumor

Phase 1

NCT02715531

Bevacizumab + interferon alfa-2b + PEG-interferon alfa-2a + ipilimumab + obinutuzumab

Anti-angiogenesis therapy + CTLA-4 antibody + targeted therapy (CD20) + other treatment

Solid tumor

Phase 1

NCT02174172

Bevacizumab + cobimetinib

Anti-angiogenesis therapy + targeted therapy (MEK1)

Gastrointestinal tumor

Phase 1

NCT02876224

Bevacizumab + sunitinib

Anti-angiogenesis therapy + targeted therapy (RTK)

RCC

Phase 2

NCT01984242

Bevacizumab + sunitinib

Anti-angiogenesis therapy + targeted therapy (RTK)

RCC

Phase 3

NCT02420821

PD-L1

Atezolizumab

5-FU + bevacizumab + carboplatin + leucovorin + nab-paclitaxel + oxaliplatin + paclitaxel + pemetrexed

Chemotherapy + anti-angiogenesis therapy

Solid tumor

Phase 1

NCT01633970

Azacitidine

Chemotherapy

Myelodysplastic syndromes

Phase 1

NCT02508870

Nab-Paclitaxel

Chemotherapy

TNBC

Phase 3

NCT02425891/IMpassion130

Carboplatin + pemetrexed

Chemotherapy

NSCLC

Phase 3

NCT02367781

Carboplatin + nab-paclitaxel + paclitaxel

Chemotherapy

NSCLC

Phase 3

NCT02367794/IMpower131

Carboplatin + cyclophosphamide

Chemotherapy

Breast cancer; cervix cancer; ovarian cancer; endometrial cancer

Phase 1

NCT02914470

Carboplatin + paclitaxel + bevacizumab

Chemotherapy + anti-angiogenesis therapy

Ovarian cancer

Phase 1, 2

NCT03394885

Bendamustine + cyclophosphamide + doxorubicin + obinutuzumab + prednisone + vincristine + rituximab

Chemotherapy + targeted therapy (CD20)

DLBCL

Phase 1, 2

NCT02596971

Carboplatin + docetaxel + pertuzumab + trastuzumab + trastuzumab emtansine + doxorubicin + cyclophosphamide

Chemotherapy + targeted therapy (HER2)

TNBC

Phase 1

NCT02605915

PD-L1

Atezolizumab

Talimogene laherparepvec

Oncolytic virus therapy

TNBC; colorectal cancer

Phase 1

NCT03256344

Radium-223 dichloride

Radiotherapy

CRPC

Phase 1

NCT02814669

HFRT

Radiotherapy

NSCLC

Early Phase 1

NCT02463994

Ciforadenant

Targeted therapy (adenosine A2A receptor)

Cancer

Phase 1

NCT02655822

Alectinib

Targeted therapy (ALK)

NSCLC

Phase 1

NCT02013219

Obinutuzumab + polatuzumab vedotin + rituximab

Targeted therapy (CD20) + targeted therapy (CD79b)

Lymphoma

Phase 1, 2

NCT02729896

Daratumumab

Targeted therapy (CD38)

NSCLC

Phase 1, 2

NCT03023423

Daratumumab + lenalidomide + pomalidomide + dexamethasone

Targeted therapy (CD38) + targeted therapy (TNF-α)

Myeloma

Phase 1

NCT02431208

Gilteritinib

Targeted therapy (FLT3/AXL)

AML

Phase 1, 2

NCT03730012

Trastuzumab emtansine

Targeted therapy (HER2)

MBC

Phase 2

NCT02924883

Cobimetinib

Targeted therapy (MEK1)

Solid Tumor

Phase 1

NCT01988896

Cobimetinib + Paclitaxel + nab-paclitaxel

Targeted therapy (MEK1) + chemotherapy

TNBC

Phase 2

NCT02322814

Cobimetinib + regorafenib

Targeted therapy (MEK1) + targeted therapy (multiple kinases)

Colorectal Cancer

Phase 3

NCT02788279

Cobimetinib + venetoclax

Targeted therapy (MEK1) + targeted therapy (Bcl-2)

Myeloma

Phase 1, 2

NCT03312530

PD-L1

Atezolizumab

Cobimetinib + vemurafenib

Targeted therapy (MEK1) + targeted therapy (BRAF)

Melanoma

Phase 1

NCT01656642

Rucaparib

Targeted therapy (PARP)

Gynecologic cancer; TNBC

Phase 1

NCT03101280

Lenalidomide + obinutuzumab

Targeted therapy (TNF-α) + targeted therapy (CD20)

Follicular lymphoma

Phase 1, 2

NCT02631577

Durvalumab

Bevacizumab

Anti-angiogenesis therapy

HER-2 negative breast cancer

Early Phase 1

NCT02802098

Paclitaxel

Chemotherapy

TNBC

Phase 1, 2

NCT02628132

Azacitidine

Chemotherapy

Solid tumor

Phase 2

NCT02811497

Nab-paclitaxel + epirubicin + cyclophosphamide

Chemotherapy

TNBC

Phase 2

NCT02685059

Tremelimumab

CTLA-4 antibody

Head and Neck cancer

Phase 3

NCT02369874

Tremelimumab

CTLA-4 antibody

Solid tumor

Phase 1

NCT02261220

Tremelimumab

CTLA-4 antibody

HER2 negative breast cancer

Phase 2

NCT02536794

Tremelimumab

CTLA-4 antibody

Breast cancer; ovarian cancer; colorectal cancer; cervical cancer; RCC

Phase 1

NCT01975831

Tremelimumab

CTLA-4 antibody

Pancreatic ductal carcinoma

Phase 2

NCT02558894

Tremelimumab

CTLA-4 antibody

NSCLC

Phase 1

NCT02000947

Tremelimumab

CTLA-4 antibody

Head and neck cancer

Phase 1

NCT02262741

PD-L1

Durvalumab

Tremelimumab

CTLA-4 antibody

Bladder cancer

Phase 2

NCT03430895

Tremelimumab

CTLA-4 antibody

Malignancy

Phase 1

NCT02978482

Tremelimumab

CTLA-4 antibody

Gastric cancer; gastroesophageal junction adenocarcinoma

Phase 1, 2

NCT02340975

Tremelimumab

CTLA-4 antibody

Colorectal cancer

Phase 2

NCT03007407

Tremelimumab

CTLA-4 antibody

Solid malignancy

Phase 1

NCT02141347

Tremelimumab

CTLA-4 antibody

Prostate cancer

Phase 2

NCT03204812

Tremelimumab + paclitaxel + carboplatin + etoposide + gemcitabine + nab-paclitaxel + 5FU + leucovorin + gemcitabine + cisplatin

CTLA-4 antibody + chemotherapy

Solid tumor

Phase 1

NCT02658214

Tremelimumab + SBRT

CTLA-4 antibody + radiotherapy

Pancreatic cancer

Phase 1, 2

NCT02311361

Mogamulizumab + tremelimumab

CTLA-4 antibody + targeted therapy (CCR4)

Solid tumor

Phase 1

NCT02301130

Tremelimumab + cetuximab + 5FU

CTLA-4 antibody + targeted therapy (EGFR) + chemotherapy

Head and Neck cancer

Phase 3

NCT02551159

Tremelimumab + AZD9150

CTLA-4 antibody + targeted therapy (STAT3)

DLBCL

Phase 1

NCT02549651

HFRT + SBRT + tremelimumab

Radiotherapy + CTLA-4 antibody

SCLC

Phase 2

NCT02701400

PD-L1

Durvalumab

Brain radiotherapy + stereotactic radiosurgery + tremelimumab + HER2 directed therapy

Radiotherapy + CTLA-4 antibody + other treatment

Breast cancer

n.a

NCT02563925

Ablation + radiotherapy + tremelimumab

Surgery + radiotherapy + CTLA-4 antibody

Colorectal cancer

Phase 2

NCT03122509

Ensartinib

Targeted therapy (ALK)

NSCLC

Phase 1, 2

NCT02898116

Dabrafenib + trametinib

Targeted therapy (BRAF) + targeted therapy (MEK1/2)

Melanoma

Phase 1

NCT02027961

Ibrutinib

Targeted therapy (brutons tyrosine kinase)

Solid tumor

Phase 1, 2

NCT02403271

Ibrutinib

Targeted therapy (brutons tyrosine kinase)

DLBCL; follicular lymphoma

Phase 1, 2

NCT02401048

Daratumumab

Targeted therapy (CD38)

Myeloma

Phase 2

NCT03000452

Pexidartinib

Targeted therapy (CSF1R)

Pancreatic cancer; colorectal cancer

Phase 1

NCT02777710

AZD5069 + nab-paclitaxel + gemcitabine

Targeted therapy (CXCR2) + chemotherapy

Pancreatic ductal adenocarcinoma

Phase 1, 2

NCT02583477

Gefitinib

Targeted therapy (EGFR)

NSCLC

Phase 1

NCT02088112

Selumetinib + tremelimumab

Targeted therapy (MEK) + CTLA-4 antibody

Solid tumor

Phase 1

NCT02586987

Eribulin

Targeted therapy (microtubule)

Breast cancer; ovarian cancer

Phase 1

NCT03430518

Olaparib

Targeted therapy (PARP)

Squamous cell carcinoma of the head and neck

Phase 2

NCT02882308

PD-L1

Durvalumab

Olaparib

Targeted therapy (PARP)

Bladder cancer

Phase 2

NCT03534492

Olaparib + bevacizumab

Targeted therapy (PARP) + anti-angiogenesis therapy

Solid tumor

Phase 1, 2

NCT02734004

Avelumab

Axitinib

Anti-angiogenesis therapy

GBM

Phase 2

NCT03291314

Axitinib

Anti-angiogenesis therapy

RCC

Phase 1

NCT02493751

Axitinib

Anti-angiogenesis therapy

HCC

Phase 1

NCT03289533

Talazoparib + chemotherapy

Chemotherapy + targeted therapy (PARP)

Ovarian cancer

Phase 3

NCT03642132

HFRT

Radiotherapy

GMB

Phase 2

NCT02968940

SAR

Radiotherapy

NSCLC

Early Phase 1

NCT03158883

Cisplatin + 5-FU + mitomycin + radiation therapy

Radiotherapy + chemotherapy

Bladder cancer

Phase 2

NCT03617913

Radiotherapy + cetuximab

Radiotherapy + chemotherapy + targeted therapy (EGFR)

Squamous cell carcinoma of the head and neck

Phase 1

NCT02938273

Magrolimab

Targeted therapy (CD47)

Ovarian cancer

Phase 1

NCT03558139

Cetuximab + gemcitabine + cisplatin + carboplatin

Targeted therapy (EGFR) + chemotherapy

NSCLC

Phase 2

NCT03717155